While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here are three cash-producing companies to avoid and some better opportunities instead.
Lamb Weston (LW)
Trailing 12-Month Free Cash Flow Margin: 8.2%
Best known for its Grown in Idaho brand, Lamb Weston (NYSE: LW) produces and distributes potato products such as frozen french fries and mashed potatoes.
Why Is LW Not Exciting?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Sales are projected to tank by 1.4% over the next 12 months as demand evaporates
- Earnings per share have dipped by 33% annually over the past three years, which is concerning because stock prices follow EPS over the long term
At $52.48 per share, Lamb Weston trades at 17.3x forward P/E. If you’re considering LW for your portfolio, see our FREE research report to learn more.
Benchmark (BHE)
Trailing 12-Month Free Cash Flow Margin: 4.8%
Operating as a critical behind-the-scenes partner for complex technology products since 1979, Benchmark Electronics (NYSE: BHE) provides advanced manufacturing, engineering, and technology solutions for original equipment manufacturers across aerospace, medical, industrial, and technology sectors.
Why Does BHE Give Us Pause?
- Annual revenue growth of 1.2% over the last two years was below our standards for the business services sector
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- ROIC of 7.4% reflects management’s challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging
Benchmark is trading at $81.00 per share, or 25x forward P/E. Read our free research report to see why you should think twice about including BHE in your portfolio.
Corcept (CORT)
Trailing 12-Month Free Cash Flow Margin: 13.7%
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Are We Hesitant About CORT?
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 16.1% annually while its revenue grew
- Free cash flow margin shrank by 24.9 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Waning returns on capital imply its previous profit engines are losing steam
Corcept’s stock price of $113.50 implies a valuation ratio of 25.7x forward P/E. Dive into our free research report to see why there are better opportunities than CORT.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
